Callan Capital LLC Buys 20 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Callan Capital LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 773 shares of the medical research company’s stock after purchasing an additional 20 shares during the quarter. Callan Capital LLC’s holdings in Thermo Fisher Scientific were worth $402,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. AMF Tjanstepension AB bought a new stake in Thermo Fisher Scientific during the third quarter valued at about $42,409,000. Howard Capital Management Group LLC raised its holdings in Thermo Fisher Scientific by 0.5% during the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company’s stock valued at $33,759,000 after acquiring an additional 286 shares during the period. Silver Oak Securities Incorporated raised its holdings in Thermo Fisher Scientific by 8.5% during the third quarter. Silver Oak Securities Incorporated now owns 693 shares of the medical research company’s stock valued at $429,000 after acquiring an additional 54 shares during the period. Joel Isaacson & Co. LLC raised its holdings in Thermo Fisher Scientific by 2.8% during the third quarter. Joel Isaacson & Co. LLC now owns 2,798 shares of the medical research company’s stock valued at $1,731,000 after acquiring an additional 77 shares during the period. Finally, Elwood & Goetz Wealth Advisory Group LLC bought a new stake in Thermo Fisher Scientific during the third quarter valued at about $536,000. 89.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research analyst reports. Bank of America cut their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. UBS Group raised their price objective on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Raymond James restated an “outperform” rating and set a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday, February 3rd. Citigroup raised their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company a “neutral” rating in a research report on Friday, January 31st. Finally, Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $656.86.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Stephen Williamson sold 9,825 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the completion of the transaction, the chief financial officer now directly owns 27,296 shares of the company’s stock, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 20,125 shares of company stock valued at $11,231,699. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of NYSE:TMO opened at $532.55 on Friday. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The business has a 50 day simple moving average of $548.47 and a two-hundred day simple moving average of $567.46. The firm has a market capitalization of $203.70 billion, a PE ratio of 32.22, a price-to-earnings-growth ratio of 2.99 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s payout ratio is currently 10.41%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in shares. This repurchase authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.